ArticlemedRxiv : the preprint server for health sciences2025
High Burden of Ventricular Arrhythmias and Cardiac Conduction Disease in Pediatric Patients with Pathogenic Desmin (
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Background: Pathogenic variants in the desmin gene ( Methods: We conducted a systematic review and individual patient data meta-analysis of Medline (PubMed) and Embase, including patients with pathogenic or likely pathogenic Results: Fifty-one pediatric patients were included (58.8% male; 64.7% probands; median age at first evaluation: 14.0 years [IQR 11.0-17.0], median follow-up: 5.0 years [1.0-11.5]). Among probands, 60.6% (20/33) had a heterozygous variant (20 non-frameshift/non-truncating and 2 frameshift/truncating), while the remaining 11 (33.3%) harbored biallelic genotypes (homozygous (n=8), compound heterozygous (n=3)). At presentation, 54.9% (28/51) patients had cardiomyopathy and 54.9% had skeletal myopathy. CCD occurred in 39.2% (median age: 19.0 years), sustained VA in 21.6% (median age: 18.0 years), and HF events in 37.3% (median age: 19.0 years). In total, 64.7% experienced MACE (median age: 17.0 years [13.0-19.0]), and 19.6% died during follow-up (median age: 23.5 years [14.8-28.0]). Rates of cardiomyopathy diagnosis, CCD, VA and HF events as well as composite MACE were similar between those with a heterozygous and biallelic variants (p>0.05 for all), but the latter group had nearly twice higher rate of skeletal myopathy (43.6% vs 83.3%, p=0.016). Conclusion: Pediatric
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.